New hope for rare liver cancer: Triple-Drug attack shows promise
NCT ID NCT04380545
First seen Jan 23, 2026 · Last updated May 15, 2026 · Updated 16 times
Summary
This study tests a combination of three drugs—nivolumab (an immunotherapy), fluorouracil (chemotherapy), and interferon alpha 2b (immune booster)—in people with a rare type of liver cancer called fibrolamellar carcinoma that cannot be surgically removed. The goal is to see if the combination is safe and can shrink tumors. About 15 adults and children will take part at M.D. Anderson Cancer Center.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE III HEPATOCELLULAR CARCINOMA AJCC V8 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.